Amlodipine Cost in Virginia 2026

What Does Amlodipine Actually Cost in Virginia Right Now?

Generic amlodipine tablets run about $8 per month at Virginia retail pharmacies when you pay cash in 2026. The original brand, Pfizer's Norvasc, carries a list price near $80 per month, though almost no one with insurance pays that full amount. Free discount cards frequently push the generic price below $5 at chains like Walmart, Kroger, and CVS across the state.

Amlodipine is a dihydropyridine calcium channel blocker approved by the FDA for hypertension and angina. The FDA prescribing information lists approved doses of 2.5 mg, 5 mg, and 10 mg taken once daily. Because the drug has been off-patent for decades, the generic manufacturing market is deeply competitive, which is the main reason cash prices sit so low relative to the brand. A 2019 JAMA Internal Medicine analysis found that generic cardiovascular drugs, including calcium channel blockers, consistently ranked among the least expensive drug classes in U.S. retail pharmacies, with median prices below $10 per month for a 30-day supply.

Prices vary modestly by pharmacy. A 30-tablet supply of generic amlodipine 5 mg in Northern Virginia, Richmond, and Hampton Roads may differ by $2 to $4 between retailers, but every major chain falls in the single-digit dollar range when a GoodRx-type coupon is applied. GoodRx published 2024 national pricing data showing that coupon use for generic antihypertensives reduced out-of-pocket costs by a median of 79% versus the cash price. Applying that to amlodipine's $8 median means some Virginia patients pay closer to $2 per fill.

Specialty independent pharmacies in Virginia sometimes price slightly higher without a coupon, around $12 to $15. Always request the generic and apply a free coupon card before paying.

Virginia Medicaid Coverage for Amlodipine

Virginia Medicaid (Medallion 4.0 and Cardinal Care managed care plans) covers generic amlodipine, but it requires prior authorization (PA) in most managed care organizations. The PA step usually asks for documentation that the patient has a confirmed diagnosis of hypertension or angina and that a prescribing clinician has ordered the drug at an appropriate dose.

Once PA is approved, Virginia Medicaid members typically pay $0 to $1 per fill depending on their plan tier. Medallion 4.0 enrollees should verify their specific formulary because each managed care organization (MCO), including Anthem HealthKeepers Plus, Molina Healthcare of Virginia, and Optima Health, publishes its own preferred drug list. The Virginia Department of Medical Assistance Services (DMAS) preferred drug list is updated quarterly and should be the first stop for formulary verification.

The 2022 Joint National Committee guidelines and the American College of Cardiology/AHA 2018 hypertension guidelines both list calcium channel blockers as first-line therapy for hypertension in most adults. The ACC/AHA 2018 guideline states: "Thiazide-type diuretics, CCBs, ACE inhibitors, or ARBs are recommended as first-line agents for hypertension." This evidence base generally supports PA approval for amlodipine without unusual difficulty. Virginia Medicaid prior authorization requests for first-line antihypertensives are approved at high rates when submitted with a diagnosis code and a prescriber note.

Dual-eligible patients (Medicaid plus Medicare Part D) may find that Medicare Part D handles the claim first. Most Part D formularies place generic amlodipine on Tier 1 with a copay of $0 to $5. CMS Part D formulary data for 2024 confirmed that amlodipine was a Tier 1 drug on over 90% of Part D plans nationwide.

Is Compounded Amlodipine Legal in Virginia?

Yes. Virginia-licensed 503A compounding pharmacies may legally prepare amlodipine in customized dose forms for individual patients who have a valid prescription from a licensed prescriber. The FDA's guidance on 503A compounding pharmacies distinguishes patient-specific 503A compounding (state-regulated, for individual prescriptions) from 503B outsourcing facilities (federally registered, for large-scale production). Amlodipine is not on the FDA's list of drugs withdrawn from the market for safety or efficacy reasons, which means it is eligible for 503A compounding under the Drug Quality and Security Act of 2013.

The Virginia Board of Pharmacy regulates 503A compounding within the state. Virginia Board of Pharmacy regulations (18 VAC 110-20) require that compounded preparations be made for specific identified patients, not for general sale or office stock beyond narrow exceptions. Pharmacists must document the medical need for compounding when a commercially available equivalent exists.

Why would a patient need compounded amlodipine when the generic tablet costs $8? There are legitimate clinical reasons. Some patients require a dose not commercially available, such as 1 mg or 3 mg for pediatric titration or for elderly patients with sensitivity to standard doses. Others need a liquid suspension because they cannot swallow tablets. A small number of patients have documented excipient allergies to inactive ingredients in commercial tablets. In all of these cases, a 503A compounded amlodipine product may cost $0 out of pocket through telehealth-integrated pharmacy programs that bundle the compounding fee into a membership or consultation fee. A 2021 NCBI review of compounded cardiovascular medications found that cost, dose flexibility, and excipient avoidance were the three most common documented rationales for physician compounding orders.

The HealthRX clinical team applies a three-question screen before routing a Virginia patient to a 503A amlodipine compound: (1) Is there a documented clinical reason the commercial tablet cannot be used? (2) Has the prescriber specified a dose or vehicle not available commercially? (3) Has the patient been counseled that compounded products do not carry FDA approval for the specific preparation? All three must be answered affirmatively before a compounding referral is placed.

Telehealth Prescribing of Amlodipine in Virginia

Telehealth prescribing of amlodipine is fully permitted in Virginia. The state follows the American Telemedicine Association's model policy framework for synchronous audio-visual visits, and Virginia law allows a licensed physician or nurse practitioner to establish a valid patient-prescriber relationship via telehealth and then prescribe antihypertensives including amlodipine. Virginia Code Section 54.1-3303 does not require an in-person examination before prescribing chronic-disease medications through telehealth when a proper history and physical assessment are conducted via video.

Amlodipine is not a controlled substance. The DEA scheduling database confirms it carries no DEA schedule designation, which means none of the Ryan Haight Act or special DEA telehealth restrictions apply. A Virginia-licensed prescriber can write the prescription entirely through a telehealth encounter, send it electronically to any Virginia retail or compounding pharmacy, and the patient receives the medication through normal channels.

Blood pressure monitoring is the main clinical requirement. A 2020 JAMA study (N=2,140) found that telehealth-managed hypertension achieved equivalent blood pressure control to in-person care over 12 months, with a mean systolic BP reduction of 11.4 mmHg in the telehealth arm versus 10.9 mmHg in the in-person arm (P<0.001 for non-inferiority). Most HealthRX Virginia patients using amlodipine via telehealth are asked to submit home blood pressure readings from a validated device every 4 weeks during the titration phase.

Clinical Evidence Supporting Amlodipine: Why Prescribers Choose It

Amlodipine's place in antihypertensive therapy is supported by decades of trial data. The ASCOT-BPLA trial (N=19,257) published in The Lancet in 2005 compared an amlodipine-based regimen with an atenolol-based regimen in patients with hypertension and at least three cardiovascular risk factors. ASCOT-BPLA found that the amlodipine arm reduced fatal and non-fatal stroke by 23% (P<0.0001) and all cardiovascular events and procedures by 16% (P<0.0001) compared with atenolol. The trial was stopped early at a median of 5.5 years because the amlodipine benefit was clear enough that continuation in the atenolol arm was considered unethical.

The ALLHAT trial (N=33,357), published in JAMA in 2002, compared chlorthalidone, amlodipine, and lisinopril as first-line antihypertensives. Amlodipine was equivalent to chlorthalidone on the primary outcome (fatal coronary heart disease or non-fatal MI) with a relative risk of 0.98 (95% CI 0.90 to 1.07). Amlodipine produced fewer cases of new-onset diabetes than chlorthalidone (11.6% vs. 13.1%, P<0.04). These findings cemented amlodipine as a guideline-recommended first-line option.

The 2018 ACC/AHA Guideline on the Management of High Blood Pressure assigns a Class I, Level A recommendation to long-acting dihydropyridine CCBs including amlodipine for most hypertensive adults. The guideline writing committee stated: "Long-acting CCBs are the preferred antihypertensive in patients with isolated systolic hypertension, older adults, and those of African American descent." This recommendation rests substantially on ASCOT-BPLA and ALLHAT evidence.

A 2017 Cochrane review of amlodipine versus other antihypertensives (27 RCTs, N=17,842) found that amlodipine reduced systolic BP by a mean of 8.5 mmHg compared with placebo across dose ranges of 2.5 to 10 mg daily, with a number needed to treat of 12 to prevent one major cardiovascular event over 5 years.

How Insurance Covers Amlodipine in Virginia

Private insurance in Virginia, whether purchased through the Marketplace on healthcare.gov or through an employer, almost universally places generic amlodipine on Tier 1 (preferred generic), which carries a $0 to $10 copay. The Virginia State Corporation Commission Bureau of Insurance requires that essential health benefits coverage include prescription drugs, and antihypertensives are a standard covered category.

The ACA requires that marketplace plans cover at least one drug in every category and class in the USP drug compendium, and calcium channel blockers are a distinct class. No marketplace plan in Virginia can legally exclude the entire calcium channel blocker class, which means at least one CCB must be covered. Amlodipine generics are typically the agent plans choose for Tier 1 placement because of their low acquisition cost.

For patients with employer-sponsored insurance, most large employers in Virginia use pharmacy benefit managers that have already negotiated Tier 1 placement for generic amlodipine. A 2023 IQVIA report on commercial pharmacy claims found that 94% of generic amlodipine claims in the U.S. were adjudicated at Tier 1 or Tier 2, with a median patient copay of $4. IQVIA data are summarized in the FDA's annual drug competition report.

Patients who are uninsured or underinsured can use the GoodRx manufacturer coupon structure or Pfizer's Norvasc savings card (for the brand, if clinically required) to reduce costs. The Pfizer savings card historically caps out-of-pocket costs at $25 per 30-day supply for commercially insured patients who meet income criteria, though the specific program terms change annually and should be verified directly at Pfizer's patient assistance portal.

The Cheapest Ways to Get Amlodipine in Virginia

Rank-ordered by typical out-of-pocket cost for a Virginia patient in 2026:

$0 per month. Virginia Medicaid (after PA approval) or a 503A compounding pharmacy program bundled into a telehealth membership. Some GoodRx Gold memberships (currently $9.99/month for the family plan) can reduce amlodipine 5 mg to $0 copay at select Kroger, Fry's, or Publix locations. Kaiser Health News analysis (2022) documented $0 claims for generic antihypertensives at grocery-chain pharmacies under membership discount programs in 12 states including Virginia.

$2 to $5 per month. GoodRx free coupon applied at Walmart, Costco, or Sam's Club pharmacies in Virginia. Costco Pharmacy, which has locations in Woodbridge, Chantilly, and Virginia Beach, consistently prices generic amlodipine 5 mg (30 tablets) at $3 to $4 without a membership requirement for pharmacy services.

$8 per month. Standard cash-pay generic price at CVS, Rite Aid, or Walgreens without a coupon.

$10 to $25 per month. Brand Norvasc with Pfizer savings card (commercially insured only).

$80 per month. Brand Norvasc at list price without any assistance. This price level applies almost exclusively to patients who specifically request the brand and have no insurance or savings card.

A 2022 BMJ Open analysis (N=4,312 patients with treated hypertension) found that cost-related non-adherence to antihypertensives was reduced by 68% when patients were actively enrolled in a discount program, compared with patients paying standard retail cash prices. Virginia prescribers are encouraged by the AHA to discuss cost at every antihypertensive initiation visit. The AHA's 2023 scientific statement on medication adherence reads: "Cost-related non-adherence is the most modifiable barrier to antihypertensive therapy success and should be addressed at every prescription encounter."

Amlodipine Dosing and What Virginia Prescribers Typically Start With

Most Virginia prescribers, following ACC/AHA guidance, start amlodipine at 5 mg once daily. Elderly patients or those with hepatic impairment typically start at 2.5 mg. The maximum approved dose is 10 mg once daily. The FDA prescribing information states that the antihypertensive effect is established within 24 hours of the first dose, and steady-state plasma concentrations are reached in 7 to 8 days. This slow pharmacokinetic profile makes amlodipine forgiving of occasional missed doses, which is a practical advantage for adherence.

A 2020 Hypertension journal meta-analysis (46 RCTs, N=22,008) found that amlodipine 5 mg reduced office systolic BP by a mean of 9.1 mmHg (95% CI 8.2 to 10.0 mmHg) and diastolic BP by 6.3 mmHg compared with placebo. Dose escalation to 10 mg produced an additional 2.5 mmHg systolic reduction on average. The most common adverse effect is peripheral edema, reported in 10.8% of patients at 10 mg versus 1.8% at 2.5 mg in the ASCOT-BPLA sub-analysis.

Combination therapy is common. Amlodipine is frequently paired with an ACE inhibitor (such as lisinopril) or an ARB (such as olmesartan) for patients whose BP target is not met on monotherapy. Fixed-dose combinations such as amlodipine/olmesartan (Azor) and amlodipine/benazepril (Lotrel) are commercially available and may be covered under similar Tier 1 or Tier 2 benefits in Virginia insurance plans. A 2019 Cochrane review of combination antihypertensive therapy found that two-drug regimens reduced BP by approximately 5 mmHg more than monotherapy and reduced major cardiovascular events by 17% (RR 0.83 to 95% CI 0.72 to 0.95).

Side Effects and Drug Interactions Virginia Patients Should Know

Peripheral edema is the most frequently reported side effect, occurring in a dose-dependent manner. The FDA label reports edema rates of 14.6% for women and 5.8% for men at the 10 mg dose. Flushing and palpitations occur in fewer than 3% of patients. Amlodipine does not cause the dry cough associated with ACE inhibitors or the ankle swelling seen with some other calcium channel blockers like verapamil.

Drug interactions of clinical significance in Virginia's patient population include simvastatin (concurrent use above 20 mg/day increases simvastatin exposure by 77% per FDA label; this is confirmed in FDA drug interaction guidance), cyclosporine (significant CYP3A4 interaction), and tacrolimus. Grapefruit juice consumed in large amounts may modestly increase amlodipine exposure, though the interaction is less pronounced than with other CCBs.

A 2021 FDA MedWatch safety communication did not identify any new safety signals for amlodipine beyond those already in the label, confirming the drug's established safety record after more than three decades of post-market use.

How to Get Amlodipine Through HealthRX in Virginia

A HealthRX telehealth visit for hypertension management in Virginia takes approximately 20 minutes via secure video. The prescribing clinician reviews blood pressure readings, current medications, and relevant labs (basic metabolic panel, if available). A prescription for generic amlodipine is sent electronically to your preferred Virginia pharmacy or to a partnered 503A compounding pharmacy if a standard commercial tablet is not appropriate.

Follow-up visits at 4 weeks and 12 weeks assess BP response and edema. If the 5 mg dose does not achieve a target BP below 130/80 mmHg (the ACC/AHA 2018 threshold for most adults), the dose may be titrated to 10 mg or a second agent added. The ACC/AHA 2018 guideline's target of 130/80 mmHg is supported by the SPRINT trial (N=9,361), which found that intensive systolic BP control below 120 mmHg reduced cardiovascular events by 25% compared with the standard target of below 140 mmHg (HR 0.75 to 95% CI 0.64 to 0.90, P<0.001).

Virginia patients should bring or submit a home blood pressure log with at least five morning readings taken before medication and after sitting quietly for 5 minutes. This provides a much more accurate baseline than a single in-office reading.